{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:16:43Z","timestamp":1777015003157,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"9151","license":[{"start":{"date-parts":[[1999,2,1]],"date-time":"1999-02-01T00:00:00Z","timestamp":917827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[1999,2]]},"DOI":"10.1016\/s0140-6736(98)03339-x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T00:46:25Z","timestamp":1027644385000},"page":"459-461","source":"Crossref","is-referenced-by-count":213,"title":["Tumour necrosis factor \u03b1 and interleukin 1\u03b2 in relapse of Crohn's disease"],"prefix":"10.1016","volume":"353","author":[{"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Nikolaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Hampe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"H\u00e4mling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmtraut","family":"Koop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birte","family":"Groessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Lochs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Raedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(98)03339-X_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","article-title":"Disease activity courses in a regional cohort of Crohn's disease patients","volume":"30","author":"Munkholm","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/S0140-6736(98)03339-X_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: a placebo controlled dose-ranging study","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(98)03339-X_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJM199603283341307","article-title":"Drug therapy: inflammatory bowel disease","volume":"334","author":"Hanauer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(98)03339-X_bib4","first-page":"1567","article-title":"Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease","volume":"334","author":"Belluzi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(98)03339-X_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF01297104","article-title":"Predictors of acute relapse of Crohn's disease: a laboratory and clinical study","volume":"32","author":"Wright","year":"1987","journal-title":"Dig Dis Sci"},{"key":"10.1016\/S0140-6736(98)03339-X_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter, placebo controlled study","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(98)03339-X_bib7","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/0016-5085(86)90206-4","article-title":"A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease","volume":"91","author":"Brignola","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(98)03339-X_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/gut.31.6.686","article-title":"Role of interleukin 1 in inflammatory bowel disease: enhanced production during active disease","volume":"31","author":"Ligumsky","year":"1990","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(98)03339-X_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/S0140-6736(98)03339-X_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","article-title":"Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease","volume":"94","author":"Reinecker","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/S0140-6736(98)03339-X_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(98)03339-X_bib12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor \u03b1 for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(98)03339-X_bib14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(98)03339-X_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(98)03339-X_bib16","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/0016-5085(95)90692-4","article-title":"Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease","volume":"108","author":"Schreiber","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(98)03339-X_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/01621459.1967.10482916","article-title":"On the Kolmogorov-Smirnov test for normality with mean and variance unknown","volume":"64","author":"Lillifors","year":"1967","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/S0140-6736(98)03339-X_bib18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/0140-6736(93)90882-H","article-title":"Intestinal permeability and the prediction of relapse in Crohn's disease","volume":"341","author":"Wyatt","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(98)03339-X_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/gut.32.2.174","article-title":"Microscopic activity in ulcerative colitis: what does it mean?","volume":"32","author":"Riley","year":"1991","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(98)03339-X_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067369803339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067369803339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T19:08:51Z","timestamp":1580843331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067369803339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2]]},"references-count":19,"journal-issue":{"issue":"9151","published-print":{"date-parts":[[1999,2]]}},"alternative-id":["S014067369803339X"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(98)03339-x","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[1999,2]]}}}